Panel Discussion: Evaluating the Strengths & Limitations of Genetic, Stem Cell, Small Molecule & RNA-Based Muscle Disease Therapies
3:45 pm - Wednesday 27th January 2027
- Examining the use of different modalities to address the underlying drivers of muscle degeneration and guide development decisions
- Debating the practical trade-offs between administration, manufacturing and patient accessibility to understand the implications of each modality
- Sharing cross-modality learnings from clinical and translational programsto identify common barriers to pipeline advancement
